For millions of men with benign prostatic hyperplasia (BPH), a common condition where the prostate gland enlarges with age, a single medication often isn't enough to control frustrating urinary symptoms like frequent nighttime bathroom trips and urgency. A new study reveals that combining a second medication with standard prostate treatment can dramatically improve these symptoms, offering hope to men who feel stuck despite being on medication. What Is BPH and Why Do Standard Treatments Sometimes Fall Short? Benign prostatic hyperplasia affects millions of men over 50, causing the prostate gland to press on the urethra and trigger overactive bladder (OAB) symptoms. These include frequent urination, urgency, nocturia (waking multiple times at night to urinate), and incomplete bladder emptying. Doctors typically start men on alpha-1 blockers, a class of medications that relax the muscles in the prostate and bladder neck to improve urine flow. However, many men continue experiencing bothersome overactive bladder symptoms even after weeks of treatment with these drugs alone. This treatment gap has left many men frustrated, wondering if their symptoms are simply something they have to live with. The new VATON study, a multi-center randomized controlled trial, tested whether adding a second medication could bridge this gap for men whose symptoms persist despite alpha-1 blocker therapy. How Does the Two-Drug Approach Work Better Than One? The study involved 158 men aged 50 and older who had been taking alpha-1 blockers for at least eight weeks but still experienced persistent overactive bladder symptoms. Researchers randomly assigned 79 men to continue their alpha-1 blocker alone, while the other 79 men added vibegron, a newer medication that works through a different mechanism in the bladder. The results were striking. Men taking the combination therapy showed significantly greater improvement in their overactive bladder symptom score compared to those on monotherapy. The two-drug group experienced a 3.3-point improvement in their symptom score, while the single-drug group improved by just 1.9 points. This difference of 1.4 points may sound modest, but it translates to meaningful relief in daily life, such as fewer nighttime bathroom trips and reduced urgency. Beyond the primary symptom score, men in the combination group reported higher satisfaction with their treatment. They also showed improvements across multiple secondary measures, including bladder diary parameters and quality-of-life scores related to urinary symptoms. Steps to Take If You're Struggling With Persistent Prostate Symptoms - Track Your Symptoms: Keep a bladder diary for a few days, noting how many times you urinate during the day and night, and when you experience urgency. This information helps your doctor understand whether your current treatment is working. - Give Your Current Medication Time: Alpha-1 blockers typically require at least eight weeks to show full benefit, so don't assume your treatment has failed too quickly. - Discuss Combination Therapy With Your Doctor: If you've been on an alpha-1 blocker for eight weeks or longer and still experience bothersome overactive bladder symptoms, ask your doctor whether adding vibegron or another complementary medication might help. - Report All Symptoms Honestly: Tell your healthcare provider about nighttime bathroom trips, urgency, incomplete emptying, and how these symptoms affect your sleep and daily activities, as this helps guide treatment decisions. Is the Two-Drug Combination Safe? Safety was a key concern in the VATON study, and the results were reassuring. Vibegron was well tolerated when added to alpha-1 blocker therapy, with no serious drug-related adverse events reported in either group. This safety profile is important because men with BPH are often older and may be taking other medications, making drug interactions a legitimate concern. The tolerability of the combination approach means that men who haven't found relief with single-drug therapy now have a viable option that doesn't introduce significant new risks. This opens the door for more men to achieve symptom control without resorting to more invasive treatments. What Does This Mean for Men With Persistent Symptoms? The VATON study provides strong evidence that a one-size-fits-all approach to BPH treatment isn't always effective. For the substantial number of men whose symptoms persist despite alpha-1 blocker monotherapy, combination treatment with vibegron offers a practical next step. Rather than accepting ongoing symptoms or jumping to surgical interventions, men now have a well-studied, safe medication option that can meaningfully improve their quality of life. If you're a man over 50 experiencing persistent urinary urgency, frequent nighttime bathroom trips, or other bothersome lower urinary tract symptoms despite being on prostate medication, this research suggests a conversation with your doctor about combination therapy is worth having. The evidence shows that adding the right second medication can make a real difference in how you feel and function day to day.
